MagForce AG is a pioneer in the area of nanotechnology-based cancer treatment. It is the first company in the
world to receive European approval for a medical product using nanoparticles. In Germany, this innovative therapy
is available to patients at the NanoTherm™ therapy centers at the Charité-Universitätsmedizin hospital in Berlin,
and the university hospitals Münster, Kiel, Cologne and Frankfurt. Additional therapy centers in Germany are
planned for 2015.

 

In March 2014, MagForce AG has incorporated an US affiliate, MagForce USA Inc., based in Nevada to develop
NanoTherm™ therapy for the treatment of glioblastoma and prostate cancer in the US and later to introduce it to
the US market.